Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 17,818 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: dose level 3 Clear all

Conditions: Leukemia, Lymphoma
Interventions: Pentostatin, Tacrolimus, Methotrexate; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Rheumatoid Arthritis
Interventions: LY2127399, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,004 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 77
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more

Conditions: Healthy Volunteers
Interventions: UK-453,061, Raltegravir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Diseases, Non-Hodgkins Lymphoma, Hodgkins Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome
Interventions: Fludarabine monophosphate, Busulfan, Stem Cell Infusion, Tacrolimus, Methotrexate, G-CSF; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 5 Years to 75 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Amyotrophic Lateral Sclerosis
Interventions: NP001, Placebo; Drug
Lead sponsor: Neuraltus Pharmaceuticals, Inc.; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 3
States / cities: San Francisco, California • Kansas City, Kansas • Lexington, Kentucky

Conditions: Advanced Solid Tumor, Non-small Cell Lung Cancer (NSCLC)
Interventions: Epacadostat, sirolimus; Drug
Lead sponsor: Chao Huang; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Fairway, Kansas • Westwood, Kansas

Conditions: Acute Myeloid Leukemia/Myelodysplastic Syndrome, Multiple Myeloma (MM)
Interventions: NKR-2 cells; Biological
Lead sponsor: Celyad Oncology SA; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Tampa, Florida • Buffalo, New York

Conditions: Rheumatoid Arthritis
Interventions: peficitinib, methotrexate; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Anniston, Alabama

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Setanaxib, Pembrolizumab, Placebo; Drug · Biological
Lead sponsor: Calliditas Therapeutics Suisse SA; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: Miami Beach, Florida • City of Saint Peters, Missouri • Creve Coeur, Missouri + 2 more

Conditions: Acute Myeloid Leukemia
Interventions: clofarabine, Ara-C; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 60 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 3
States / cities: Birmingham, Alabama • Omaha, Nebraska • Cleveland, Ohio

Conditions: Brain Injuries, Traumatic
Interventions: Propranolol; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Solid Tumors
Interventions: Sterile Compound C31510 for Injection; Drug
Lead sponsor: BPGbio; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Transplant; Failure, Kidney
Interventions: Tacrolimus, Everolimus, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids; Drug
Lead sponsor: Gaetano Ciancio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Mixed Mullerian Tumors of the Uterus
Interventions: Gemcitabine, Oxaliplatin, Radiation; Drug · Radiation
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Smoking, Smoking Cessation, Nicotine Dependence
Interventions: Counseling before quit attempt, Minimal In-person counseling during quit attempt, Intensive in-person counseling during the quit attempt, Minimal phone counseling during the quit attempt, Intensive phone counseling during the quit attempt, Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt, Short Term Nicotine Patch + Nicotine Gum during the quit attempt, Pre-Quit Nicotine Gum, Pre-Quit Nicotine Patch, Pre-Quit Nicotine Patch + Pre-Quit Nicotine Gum; Behavioral · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 99 Years
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Alzheimer Disease, Chronic Traumatic Encephalopathy
Interventions: [F-18]Flornaptitril; Drug
Lead sponsor: CereMark Pharma, LLC; Industry
Eligibility: 45 Years and older
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Major Depressive Disorder
Interventions: (2R,6R)-Hydroxynorketamine hydrochloride, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Sorafenib; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
Interventions: Ruxolitinib, Duvelisib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 9
States / cities: Miami, Florida • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more

Conditions: Malignant Disease
Interventions: MP-470 + topotecan, MP-470 + docetaxel, MP-470 + erlotinib, MP-470 + paclitaxel/carboplatin, MP-470 + carboplatin/etoposide; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 5
States / cities: Scottsdale, Arizona • Santa Monica, California • San Antonio, Texas

Conditions: Pharyngitis
Interventions: placebo, flurbiprofen, acetaminophen 650mg; Drug
Lead sponsor: Reckitt Benckiser LLC; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Pruritus, Uremic Pruritus
Interventions: Part A: Placebo, Part A: CR845 0.5 mcg/kg, Part A: CR845 1.0 mcg/kg, Part A: CR845 2.5 mcg/kg, Part B: Placebo, Part B: CR845 1.0 mcg/kg; Drug
Lead sponsor: Cara Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 20
States / cities: Pine Bluff, Arkansas • Chula Vista, California • Long Beach, California + 17 more

Conditions: Hepatic Impairment
Interventions: Mitiperstat; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Rialto, California • Hialeah, Florida • Orlando, Florida + 2 more

Conditions: Healthy Subjects
Interventions: Placebo, MEDI7814, 1 MG/KG, MEDI7814, 3 MG/KG, MEDI7814, 10 MG/KG, MEDI7814, 20 MG/KG; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Search by objective public record fields.

Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT

A Rheumatoid Arthritis Study in Participants

Drug Interaction Study Between Raltegravir And UK-453,061

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)

Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis

A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia

Beta Blockade in in Traumatic Brain Injury

Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus

Identifying Optimal Smoking Cessation Intervention Components (Cessation)

Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

Sorafenib in Treating Patients With Advanced Malignant Solid Tumors

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors

A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis

Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers